Therapeutic Vaccines: Strong Innovation But Far Away From Capitalization

Table of Contents

CHAPTER 1 EXECUTIVE SUMMARY

• Scope
• Datamonitor' s Insight into the Therapeutic Antibodies market in 2003
• The therapeutic vaccine market will not receive significant attention from the wider pharmaceutical industry until a product is launched and achieves significant uptake across the seven major markets
• For companies that are totally focused on therapeutic vaccines, the only way to survive is through a strong network of partners
• Oncology dominates the therapeutic vaccine market both in terms of commercial potential and pipeline development
• The industry is taking two routes to market through the development of generalized and personalized vaccines. While personalized vaccines offer greater selectivity and lower side effects, generalized vaccines offer improved economies of scale.

CHAPTER 2 IDENTIFYING AND EXPLOITING FUTURE GROWTH OPPORTUNITIES

• Key findings
• Introduction
• Drivers of therapeutic vaccine innovation
• Therapeutic strategy – targeting oncology
• Target discovery – greater understanding through use of genomics
• Antigen selection – from single to multiple and native to synthetic
• Personalized vs generalized vaccine development
• Vaccine design – from naked to encapsulated forms
• Optimizing efficacy – adjuncts to maximize immune response
• Therapeutic vaccine business model evolution
• Is focusing 100% on therapeutic vaccines a sustainable business model?
• From early drug development to full integration
• Alliance networks are essential for innovative therapeutic vaccine players to survive
• Late stage pipeline analysis
• Drivers and resistors of collaborating on the development and marketing of therapeutic vaccines
• Drivers of collaborations
• Resistors to partnering
• Large pharma involvement
• Merger and acquisitions – a strategy for growth?
• M&A for horizontal integration
• M&A for vertical integration
• M&A for survival
• CHAPTER 3 MARKET ANALYSIS, 2002-08
• Key findings
• Therapeutic vaccine market size, 2002
• Therapeutic vaccine market to 2008
• Scenario forecasts
• Most likely scenario, year-on-year forecasts, 2002-08
• Shape of the therapeutic vaccine pipeline
• Therapeutic analysis – oncology dominates the late stage and full pipeline of therapeutic vaccines
• High unmet need and the mechanism of action of therapeutic vaccines has driven the interest in cancer indications
• CHAPTER 4 THERAPEUTIC VACCINE COMPANY ANALYSIS
• Key findings
• Benchmarking the leading players
• Antigenics
• Key findings
• Company strategy
• Technology platform
• Portfolio and pipeline analysis
• Aphton
• Key findings
• Company strategy
• Technology platform
• Portfolio and pipeline analysis
• Biomira
• Key findings
• Company strategy
• Technology platform
• Portfolio and pipeline analysis
• Corixa
• Key findings
• Company strategy
• Technology platform
• Portfolio and pipeline analysis
• Dendreon
• Key findings
• Company strategy
• Technology platform
• Portfolio and pipeline analysis
• Therion Biologics
• Key findings
• Company strategy
• Technology platform
• Portfolio and pipeline analysis
• CHAPTER 5 APPENDIX
• Report methodology
• Exchange rates
• About Datamonitor
• About Datamonitor Healthcare
• Datamonitor Healthcare' s research and analysis methodologies
• Datamonitor Healthcare' s therapy area capabilities
• Datamonitor' s Competitive Intelligence Business Unit

List of Tables

Table 1: Therapeutic vaccine market, 2002

Table 2: Scenario forecast growth of the therapeutic vaccine market

Table 3: Most likely scenario, year-on-year forecasts, 2002-08

Table 4: Antigenics' s therapeutic vaccine and adjuvant pipeline, 2003

Table 5: Aphton' s pipeline, 2003

Table 6: Biomira' s pipeline 2003

Table 7: Corixa' s pipeline, 2003

Table 8: Dendreon' s therapeutic vaccine pipeline

Table 9: Therion Biologics pipeline, 2003

Table 10: Exchange rates, 2002

List of Figures

Figure 1: In the best case scenario, the therapeutic vaccine market could be worth $719m by 2008

Figure 2: The factors inhibiting pharmaceutical companies partnering therapeutic vaccine players significantly outweigh the drivers

Figure 3: Colorectal, melanoma and prostate cancer have the most therapeutic vaccines in development

Figure 4: Personalized versus generalized vaccines: ethical sales, 2002-08

Figure 5: The evolution of immunology-based medicine

Figure 6: Key product development trends

Figure 7: Therapeutic vaccine pipeline distribution according to therapeutic focus, 2003

Figure 8: Commercial therapeutic focus of the therapeutic vaccine market

Figure 9: New therapeutic vaccine approvals according to therapeutic focus, 2003-08

Figure 10: Personalized versus generalized vaccines: ethical sales, 2002-08

Figure 11: Personalized versus generalized approaches: product approval trajectories

Figure 12: Distribution of high, medium and low personalized and generalized earners in terms of ethical sales by 2008

Figure 13: Business model variability according to technological focus, and business diversification, 2003

Figure 14: Distribution of therapeutic vaccine players according to their degree of business integration, 2003

Figure 15: Therapeutic protein companies are being forced to take on greater risk in drug development for a lower return

Figure 16: The overall influence of drivers and resistors to form partnerships for therapeutic vaccines is negative

Figure 17: Aventis is collaborating with five companies as part of its therapeutic vaccine development program

Figure 18: In the best case scenario, the therapeutic vaccine market could be worth $719m by 2008

Figure 19: Competition will increase beyond 2008, with 50 novel products in Phase I/II and Phase II development

Figure 20: Oncology therapies dominate the therapeutic vaccine market

Figure 21: The therapeutic vaccine early stage pipeline is split across more therapy areas, compared to the late stage and marketed

Figure 22: Colorectal, melanoma and prostate cancer have the most therapeutic vaccines in development

Figure 23: Antigenics has the strongest pipeline, with a strong Phase III candidate and two Phase II products as back up

Figure 24: Corixa is the most diversified company, having other businesses with marketed products

Figure 25: Aphton has the strongest alliance network

Figure 26: Aphton was in the weakest position financially in 2002

Figure 27: Aphton is the most favorably positioned company for future growth

Figure 28: Antigenics' s strategic position relating to its therapeutic vaccine business, 2003

Figure 29: Antigenics' s alliance network

Figure 30: The core of Antigenics' s vaccine development engine

Figure 31: SWOT analysis for Aphton

Figure 32: Aphton' s alliance network

Figure 33: The core of Aphton' s vaccine development engine

Figure 34: SWOT analysis for Biomira

Figure 35: Biomira' s alliance network

Figure 36: The core of Biomira' s technological expertise

Figure 37: Corixa' s strategic position, 2003

Figure 38: Corixa' s alliance network relating to its therapeutic vaccine and adjuvant businesses.

Figure 39: The core of Corixa' s vaccine development engine

Figure 40: Dendreon' s strategic position, relating to its therapeutic vaccine business, 2003

Figure 41: Dendreon' s therapeutic vaccine alliance network

Figure 42: The core of Dendreon' s vaccine development engine

Figure 43: SWOT analysis for Therion

Figure 44: Therion' s alliance network

Figure 45: The structure of Therion' s vaccine development engine